These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 31751656)

  • 1. Effects on pancreatic Beta and other Islet cells of the glucose-dependent insulinotropic polypeptide.
    Khan R; Tomas A; Rutter GA
    Peptides; 2020 Mar; 125():170201. PubMed ID: 31751656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of GIP in α-cells and glucagon secretion.
    El K; Campbell JE
    Peptides; 2020 Mar; 125():170213. PubMed ID: 31785304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice.
    Maida A; Hansotia T; Longuet C; Seino Y; Drucker DJ
    Gastroenterology; 2009 Dec; 137(6):2146-57. PubMed ID: 19766644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
    Skow MA; Bergmann NC; Knop FK
    Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The glucose-dependent insulinotropic polypeptide signaling axis in the central nervous system.
    Adriaenssens AE; Gribble FM; Reimann F
    Peptides; 2020 Mar; 125():170194. PubMed ID: 31697967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and β cell preservation.
    Yabe D; Seino Y
    Prog Biophys Mol Biol; 2011 Nov; 107(2):248-56. PubMed ID: 21820006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of chronic exposure of clonal β-cells to elevated glucose and free fatty acids on incretin receptor gene expression and secretory responses to GIP and GLP-1.
    Pathak V; Vasu S; Flatt PR; Irwin N
    Diabetes Obes Metab; 2014 Apr; 16(4):357-65. PubMed ID: 24164718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced Endosomal Signaling and Desensitization of GLP-1R vs GIPR in Pancreatic Beta Cells.
    Manchanda Y; Bitsi S; Chen S; Broichhagen J; Bernardino de la Serna J; Jones B; Tomas A
    Endocrinology; 2023 Mar; 164(5):. PubMed ID: 36774542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular biology of the GIP receptor.
    Greenwell AA; Chahade JJ; Ussher JR
    Peptides; 2020 Mar; 125():170228. PubMed ID: 31812593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents.
    Gasbjerg LS; Gabe MBN; Hartmann B; Christensen MB; Knop FK; Holst JJ; Rosenkilde MM
    Peptides; 2018 Feb; 100():173-181. PubMed ID: 29412817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
    Green BD; Gault VA; O'Harte FP; Flatt PR
    Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of Glucose-dependent Insulinotropic Polypeptide (GIP) on human adipose tissue and fat metabolism: Implications for obesity, type 2 diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD).
    Thondam SK; Cuthbertson DJ; Wilding JPH
    Peptides; 2020 Mar; 125():170208. PubMed ID: 31759125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.
    Nauck MA; Quast DR; Wefers J; Pfeiffer AFH
    Diabetes Obes Metab; 2021 Sep; 23 Suppl 3():5-29. PubMed ID: 34310013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The entero-insular axis: implications for human metabolism.
    Ranganath LR
    Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucose-dependent insulinotropic polypeptide is expressed in pancreatic islet alpha-cells and promotes insulin secretion.
    Fujita Y; Wideman RD; Asadi A; Yang GK; Baker R; Webber T; Zhang T; Wang R; Ao Z; Warnock GL; Kwok YN; Kieffer TJ
    Gastroenterology; 2010 May; 138(5):1966-75. PubMed ID: 20138041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the insulinotropic and glucose-lowering actions of zebrafish GIP in mammalian systems: Evidence for involvement of the GLP-1 receptor.
    Graham GV; Conlon JM; Abdel-Wahab YH; Gault VA; Flatt PR
    Peptides; 2018 Feb; 100():182-189. PubMed ID: 29157578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis.
    Pamir N; Lynn FC; Buchan AM; Ehses J; Hinke SA; Pospisilik JA; Miyawaki K; Yamada Y; Seino Y; McIntosh CH; Pederson RA
    Am J Physiol Endocrinol Metab; 2003 May; 284(5):E931-9. PubMed ID: 12540373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel GLP-1/xenin hybrid peptide improves glucose homeostasis, circulating lipids and restores GIP sensitivity in high fat fed mice.
    Hasib A; Ng MT; Khan D; Gault VA; Flatt PR; Irwin N
    Peptides; 2018 Feb; 100():202-211. PubMed ID: 29412820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice.
    Parker JC; Lavery KS; Irwin N; Green BD; Greer B; Harriott P; O'Harte FP; Gault VA; Flatt PR
    J Endocrinol; 2006 Oct; 191(1):93-100. PubMed ID: 17065392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pathogenic role of the GIP/GIPR axis in human endocrine tumors: emerging clinical mechanisms beyond diabetes.
    Regazzo D; Barbot M; Scaroni C; Albiger N; Occhi G
    Rev Endocr Metab Disord; 2020 Mar; 21(1):165-183. PubMed ID: 31933128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.